Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Ventricular Dysfunction 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myeloid, Acute 1Hypertension 1Essential Hypertension 1Cardiotoxicity 1Breast Neoplasms 1

Interventions

Doxorubicin 6Dexrazoxane 6Razoxane 5Vincristine 4Cyclophosphamide 4Radiotherapy 3Etoposide 3Prednisone 2Methotrexate 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Carvedilol 2Bleomycin 2schizandrin 1pegfilgrastim 1hydrocortisone hemisuccinate 1fructus schizandrae, radix ginseng, radix ophiopogonis drug combination 1empagliflozin 1Watchful Waiting 1VAP-cyclo protocol 1Trastuzumab 1Taxes 1Tamoxifen 1Rituximab 1Ramipril 1Radiation 1Prednisolone 1Paclitaxel 1Observation 1Neoadjuvant Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Cardiotoxicity × Enalapril × Clear all
NCT00003070 2014-08-05

Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer

Children's Oncology Group

Phase 3 Completed
13 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡